Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 28
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Modeling the Number of People Infected With SARS-COV-2 From Wastewater Viral Load in Northwest Spain

  • Vallejo, J. A.
  • Trigo Tasende, Noelia
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • López-Oriona, Ángel
  • Barbeito, Inés
  • Vaamonde, Manuel
  • Tarrío-Saavedra, Javier
  • Reif López, Rubén
  • Ladra, Susana
  • Rodiño-Janeiro, Bruno Kotska
  • Nasser-Ali, Mohammed
  • Cid, Ángeles
  • Veiga, María Carmen
  • Acevedo, Antón
  • Lamora, Carlos
  • Bou, Germán
  • Cao, Ricardo
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract] The quantification of the SARS-CoV-2 RNA load in wastewater has emerged as a useful tool to monitor COVID–19 outbreaks in the community. This approach was implemented in the metropolitan area of A Coruña (NW Spain), where wastewater from a treatment plant was analyzed to track the epidemic dynamics in a population of 369,098 inhabitants. Viral load detected in the wastewater and the epidemiological data from A Coruña health system served as main sources for statistical models developing. Regression models described here allowed us to estimate the number of infected people (R2 = 0.9), including symptomatic and asymptomatic individuals. These models have helped to understand the real magnitude of the epidemic in a population at any given time and have been used as an effective early warning tool for predicting outbreaks in A Coruña municipality. The methodology of the present work could be used to develop a similar wastewater-based epidemiological model to track the evolution of the COVID–19 epidemic anywhere in the world where centralized water-based sanitation systems exist., This work was supported by EDAR Bens S.A., A Coruña, Spain [grant references INV04020, INV12120 and INV05921 to MP], the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 funded by the ISCIII, Spain - General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant numbers PI15/00860 to GB, PI17/01482 and PI20/00413 to MP], the GAIN, Xunta de Galicia, Spain [grant number IN607A 2016/22 to GB, ED431C-2016/015 and ED431C-2020/14 to RC, ED431C 2017/58 to SL, ED431G 2019/01 to RC and SL, and ED431C 2017/66 to MCV], MINECO, Spain [grant number MTM2017-82724-R to RC], Ministerio de Ciencia e Innovación, Spain [grant number PID2020-113578RB-100 to RC], and the Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/006 to GB]. The work was also supported by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 - Research and Innovation Framework Programme under grant agreement no 871029. SR-F was financially supported by REIPI RD16/0016/006, KC-P by IN607A 2016/22 and the Spanish Association against Cancer (AECC) and JAV by IN607A 2016/22. Funding for open access charge: Universidade da Coruña/CISUG, EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2017/58, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; ED431C 2017/66
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Global transcriptomic analysis during murine pneumonia infection reveals new virulence factors in Acinetobacter baumannii

  • Martínez Guitián, Marta
  • Vázquez-Ucha, Juan Carlos
  • Álvarez-Fraga, Laura
  • Conde-Pérez, Kelly
  • Vallejo, J. A.
  • Perina Cedrón, Alejandra
  • Bou, Germán
  • Poza, Margarita
  • Beceiro Casas, Alejandro
[Abstract] Background: Infections caused by multidrug-resistant pathogens such as Acinetobacter baumannii constitute a major health problem worldwide. In this study we present a global in vivo transcriptomic analysis of A. baumannii isolated from the lungs of mice with pneumonia infection. Methods: Mice were infected with A. baumannii ATCC 17978 and AbH12O-A2 strains and the total bacterial RNA were analyzed by RNA sequencing. Lists of differentially expressed genes were obtained and 14 of them were selected for gene deletion and further analysis. Results: Transcriptomic analysis revealed a specific gene expression profile in A. baumannii during lung infection with upregulation of genes involved in iron acquisition and host invasion. Mutant strains lacking feoA, mtnN, yfgC, basB, hisF, oatA, and bfnL showed a significant loss of virulence in murine pneumonia. A decrease in biofilm formation, adherence to human epithelial cells, and growth rate was observed in selected mutants. Conclusions: This study provides an insight into A. baumannii gene expression profile during murine pneumonia infection. Data revealed that 7 in vivo upregulated genes were involved in virulence and could be considered new therapeutic targets., This work was supported by Instituto de Salud Carlos III (PI15/00860 and PI18/00501 to G. B. and PI14/00059 and PI17/01482 to A. B. and M. P.); Axencia Galega de Innovacion- Consellería de Economía, Emprego e Industria (IN607A 2016/22 to G. B); Spanish Network for Research in Infectious Diseases and European Development Regional Fund (REIPI RD16/0016/006 and FI18/00315 to J. C. V.-U); M. M.-G. was supported by the Spanish Society of Clinical Microbiology and Infectious Diseases (Clara Roy grant); and K. C.-P. was supported by the Spanish Association Against Cancer.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Wastewater early warning system for SARS-CoV-2 outbreaks and variants in a Coruña, Spain

  • Trigo Tasende, Noelia
  • Vallejo, J. A.
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • Vaamonde, Manuel
  • López-Oriona, Ángel
  • Barbeito, Inés
  • Nasser-Ali, Mohammed
  • Reif López, Rubén
  • Rodiño-Janeiro, Bruno Kotska
  • Fernández-Álvarez, Elisa
  • Iglesias Corrás, Iago
  • Tarrío-Saavedra, Javier
  • Tomás, Laura
  • Gallego-García, Pilar
  • Posada, David
  • Bou, Germán
  • López-de-Ullibarri, Ignacio
  • Cao, Ricardo
  • Susana, Ladra
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract]: Wastewater-based epidemiology has been widely used as a cost-effective method for tracking the COVID-19 pandemic at the community level. Here we describe COVIDBENS, a wastewater surveillance program running from June 2020 to March 2022 in the wastewater treatment plant of Bens in A Coruña (Spain). The main goal of this work was to provide an effective early warning tool based in wastewater epidemiology to help in decision-making at both the social and public health levels. RT-qPCR procedures and Illumina sequencing were used to weekly monitor the viral load and to detect SARS-CoV-2 mutations in wastewater, respectively. In addition, own statistical models were applied to estimate the real number of infected people and the frequency of each emerging variant circulating in the community, which considerable improved the surveillance strategy. Our analysis detected 6 viral load waves in A Coruña with concentrations between 103 and 106 SARS-CoV-2 RNA copies/L. Our system was able to anticipate community outbreaks during the pandemic with 8-36 days in advance with respect to clinical reports and, to detect the emergence of new SARS-CoV-2 variants in A Coruña such as Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529 and BA.2) in wastewater with 42, 30, and 27 days, respectively, before the health system did. Data generated here helped local authorities and health managers to give a faster and more efficient response to the pandemic situation, and also allowed important industrial companies to adapt their production to each situation. The wastewater-based epidemiology program developed in our metropolitan area of A Coruña (Spain) during the SARS-CoV-2 pandemic served as a powerful early warning system combining statistical models with mutations and viral load monitoring in wastewater over time., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Funding for open access charge: Universidade da Coruña/CISUG. This work was supported by EDAR Bens S.A., A Coruña, Spain [grant references INV04020, INV12120, INV05921, and INV148721 to MP], by the National Plan for Scientific Research, Development and Technological Innovation funded by the Institute of Health Carlos III (ISCIII), Spain—General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant references PI15/00860 to GB, PI17/01482, and PI20/00413 to MP], by the Galician Innovation Agency (GAIN) (Xunta de Galicia, Spain) [grant references IN607A 2016/22 to GB, ED431C-2016/015 and ED431C-2020/14 to RC, ED431C 2021/53 to SL and ED431G 2019/01 and COV20/00604 to RC and SL, by Ministry of Economic Affairs and Digital Transformation (MINECO), Spain [grant references MTM2017-82724-R to RC], by the Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0006 to GB], by the “Innova Saúde” Program, (INNOVAMICROLAB project) co-founded by the Galician Healthcare Service (SERGAS) and the Spanish Ministry of Science and Innovation, and by the Spanish Network of Research in Infectious Diseases (CIBERINFEC, ISCIII), and by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 871029. SR-F was financially supported by REIPI RD16/0016/006, KC-P by IN607A 2016/22 and the Spanish Association against Cancer (AECC) and JAV by IN607A 2016/22. DP was funded by grant EPICOVIGAL FONDO SUPERA-COVID19 from Banco Santander-CSIC-CRUE, Spain, and grant CT850A-2 from (Health Knowledge Agency) ACIS SERGAS from the Consellería de Sanidade of Xunta de Galicia, Spain., EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, EDAR Bens S.A.; INV148721, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2021/53, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; COV20/00604
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Analysis of the Role of the LH92_11085 Gene of a Biofilm Hyper-Producing Acinetobacter baumannii Strain on Biofilm Formation and Attachment to Eukaryotic Cells

  • Álvarez-Fraga, Laura
  • Pérez Gómez, Astrid
  • Rumbo-Feal, Soraya
  • Merino Carballeira, María
  • Vallejo, J. A.
  • Ohneck, Emily J.
  • Edelmann, Richard E.
  • Beceiro Casas, Alejandro
  • Vázquez-Ucha, Juan Carlos
  • Valle, Jaione
  • Actis, Luis
  • Bou, Germán
  • Poza, Margarita
[Abstract] Acinetobacter baumannii is a nosocomial pathogen that has a considerable ability to survive in the hospital environment partly due to its capacity to form biofilms. The first step in the process of establishing an infection is adherence of the bacteria to target cells. Chaperone-usher pili assembly systems are involved in pilus biogenesis pathways that play an important role in adhesion to host cells and tissues as well as medically relevant surfaces. After screening a collection of strains, a biofilm hyper-producing A. baumannii strain (MAR002) was selected to describe potential targets involved in pathogenicity. MAR002 showed a remarkable ability to form biofilm and attach to A549 human alveolar epithelial cells. Analysis of MAR002 using transmission electron microscopy (TEM) showed a significant presence of pili on the bacterial surface. Putative protein-coding genes involved in pili formation were identified based on the newly sequenced genome of MAR002 strain (JRHB01000001/2 or NZ_JRHB01000001/2). As assessed by qRT-PCR, the gene LH92_11085, belonging to the operon LH92_11070-11085, is overexpressed (ca. 25-fold more) in biofilm-associated cells compared to exponential planktonic cells. In the present work we investigate the role of this gene on the MAR002 biofilm phenotype. Scanning electron microscopy (SEM) and biofilm assays showed that inactivation of LH92_11085 gene significantly reduced bacterial attachment to A549 cells and biofilm formation on plastic, respectively. TEM analysis of the LH92_11085 mutant showed the absence of long pili formations normally present in the wild-type. These observations indicate the potential role this LH92_11085 gene could play in the pathobiology of A baumannii., The results of this work have been funded by the Projects PI11/01034 to MP and PI14/00059 to MP and AB and PI12/00552 and PI15/00860 to GB, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 and funded by the ISCIII- General Subdirection of Assessment and Promotion of the Research – European Regional Development Fund (FEDER) “A way of making Europe” and Miami University (Ohio, USA) Research Funds. We also thank Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014 to GB), cofinanced by the European Development Regional Fund (EDRF) “A Way to Achieve Europe, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad. A.P. was financially supported by the Galician Plan for Research, Innovation and Growth (I2C Plan 2012-2016). J.A. Vallejo was financially supported by the Sara Borrell Program (ISCIII, Spain CD13/00373). We wish to thank grant GEIH/REIPI-Ab2010 from Instituto de Salud Carlos III - Ministerio Economía y Competitividad for providing MAR002 strain and M.I. Voskuil for pMo130.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Towards the early detection of β-lactamase-producing Enterobacteriaceae by MALDI-TOF MS analysis

  • Oviaño, Marina
  • Gómara, Marta
  • Barba, María José
  • Revillo, María José
  • Barbeyto, Luis Pedro
  • Bou, Germán
[Abstract] Objectives: Development of a novel MALDI-TOF MS-based method for the rapid detection of ESBL-producing Enterobacteriaceae. Methods: The method was evaluated in terms of sensitivity, specificity and turnaround time regarding the antibiotic used (cefotaxime, ceftazidime, ceftriaxone, cefpodoxime or cefepime) and the performance of the automated MBT STAR-BL software (Bruker Daltonik GmbH, Germany) relative to qualitative interpretation of spectra for detecting β-lactamase resistance by MALDI-TOF MS (Bruker Daltonik) in a collection of 11 isogenic Escherichia coli control strains expressing different β-lactamases. Finally, for clinical validation, β-lactamase activity was determined under previously evaluated conditions in 100 clinical isolates previously characterized by PCR and sequencing. Results: Clinical validation of the assay showed 100% sensitivity and specificity for detecting β-lactam resistance in 30 min by measuring hydrolysis of ceftriaxone (0.50 mg/mL) with the automated MBT STAR-BL software. Regarding the antibiotics evaluated, ceftriaxone yielded 70% more positive results than cefotaxime, 80% more than ceftazidime and 20% more than cefpodoxime, with 100% specificity. Cefepime revealed 100% sensitivity, but only 27% specificity. For the same incubation time, the automated software yielded on average 41% more positive results in relation to detecting resistance than qualitative interpretation of spectra. Conclusions: Our clinical validation of the method proved it to be highly reliable, simple to perform and time saving, transforming β-lactam resistance detection by MALDI-TOF MS into a ready-to-use technique in clinical laboratories., This work was supported by a grant from the Fondo de Investigación Sanitaria (grant number PI15/00860 to G. B.); Plan Nacional de I + D and Instituto de Salud Carlos III (ISCIII), Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0006) co-financed by European Development Regional Fund ‘A Way to Achieve Europe’ ERDF. M. O. is financially supported by the Río Hortega Programme of the ISCIII (CM15/00155). Sociedad Española de Enfermedades Infecciosas y Microbiología Clinica (SEIMC) supported relocation of M. G. to allow this work to be carried out.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

An improved matrix-assisted laser desorption ionization-time of flight mass spectrometry data analysis pipeline for the identification of carbapenemase-producing Klebsiella pneumoniae

  • Gato, Eva
  • Constanso-Conde, Ignacio
  • Candela, Ana
  • Galán, Fátima
  • Rodiño-Janeiro, Bruno Kotska
  • Arroyo, Manuel J.
  • Méndez, Gema
  • Mancera, Luis
  • Alioto, Tyler S.
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Rodríguez-Sánchez, Belén
  • Bou, Germán
  • Oviaño, Marina
[Abstract] The increasing emergence of carbapenemase-producing Klebsiella pneumoniae (CPK) isolates is a global health alarm. Rapid methods that require minimum sample preparation and rapid data analysis are urgently required. Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has recently been used by clinical laboratories for identification of antibiotic-resistant bacteria; however, discrepancies have arisen regarding biological and technical issues. The aim of this study was to standardize an operating procedure and data analysis for identification of CPK by MALDI-TOF MS. To evaluate this approach, a series of 162 K. pneumoniae isolates (112 CPK and 50 non-CPK) were processed in the MALDI BioTyper system (Bruker Daltonik, Germany) following a standard operating procedure. The study was conducted in two stages; the first is denominated the "reproducibility stage" and the second "CPK identification." The first stage was designed to evaluate the biological and technical variation associated with the entire analysis of CPK and the second stage to assess the final accuracy of MALDI-TOF MS for the identification of CPK. Therefore, we present an improved MALDI-TOF MS data analysis pipeline using neural network analysis implemented in Clover MS Data Analysis Software (Clover Biosoft, Spain) that is designed to reduce variability, guarantee interlaboratory reproducibility, and maximize the information selected from the bacterial proteome. Using the random forest (RF) algorithm, 100% of CPK isolates were correctly identified when all the peaks in the spectra were selected as input features and total ion current (TIC) normalization was applied. Thus, we have demonstrated that real-time direct tracking of CPK is possible using MALDI-TOF MS., This work was supported by funding awarded to M.O. through the Competitive Research Call 2019 of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). The research was also funded by the Fondo de Investigación Sanitaria through grants no. PI15/00860 and PI18/00860 to G.B., integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII) and by the Spanish Network of Research in Infectious Diseases (REIPI), grant no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 and funded by the ISCIII, General Subdirection of Assessment and Promotion of the Research, European Regional Development Fund (FEDER) A Way of Making Europe. M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006) and E.G. by the research call 2019 of the SEIMC.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Antisense inhibition of lpxB gene expression in Acinetobacter baumannii by peptide-PNA conjugates and synergy with colistin

  • Martínez Guitián, Marta
  • Vázquez-Ucha, Juan Carlos
  • Álvarez-Fraga, Laura
  • Conde-Pérez, Kelly
  • Bou, Germán
  • Poza, Margarita
  • Beceiro Casas, Alejandro
[Abstract] Background: LpxB is an enzyme involved in the biosynthesis pathway of lipid A, a component of LPS. Objectives: To evaluate the lpxB gene in Acinetobacter baumannii as a potential therapeutic target and to propose antisense agents such as peptide nucleic acids (PNAs) as a tool to combat bacterial infection, either alone or in combination with known antimicrobial therapies. Methods: RNA-seq analysis of the A. baumannii ATCC 17978 strain in a murine pneumonia model was performed to study the in vivo expression of lpxB. Protein expression was studied in the presence or absence of anti-lpxB (KFF)3K-PNA (pPNA). Time-kill curve analyses and protection assays of infected A549 cells were performed. The chequerboard technique was used to test for synergy between pPNA and colistin. A Galleria mellonella infection model was used to test the in vivo efficacy of pPNA. Results: The lpxB gene was overexpressed during pneumonia. Treatment with a specific pPNA inhibited LpxB expression in vitro, decreased survival of the ATCC 17978 strain and increased the survival rate of infected A549 cells. Synergy was observed between pPNA and colistin in colistin-susceptible strains. In vivo assays confirmed that a combination treatment of anti-lpxB pPNA and colistin was more effective than colistin in monotherapy. Conclusions: The lpxB gene is essential for A. baumannii survival. Anti-lpxB pPNA inhibits LpxB expression, causing bacterial death. This pPNA showed synergy with colistin and increased the survival rate in G. mellonella. The data suggest that antisense pPNA molecules blocking the lpxB gene could be used as antibacterial agents., This study was funded by projects PI15/00860 and PI18/00501 to G.B., CP13/00226 to A.B., and PI14/00059 and PI17/01482 to A.B. and M.P. (Instituto de Salud Carlos III). The study was also funded by project IN607A 2016/22 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) to G.B. Support was also provided by Planes Nacionales de I + D+i 2013–2016 and ISCIII, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund ‘A way to achieve Europe’ and the operative programme Intelligent Growth 2014–2020. J.C.V.U. was financially supported by the Miguel Servet Programme (ISCIII, Spain CP13/00226) and the pFIS Programme (FI18/00315) and M.M.G. was financially supported by a Clara Roy grant (SEIMC) and K.C.P. by IN607A 2016/22.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii

  • Vázquez-Ucha, Juan Carlos
  • Maneiro Rey, María
  • Martínez Guitián, Marta
  • Buynak, John
  • Bethel, Christopher R.
  • Bonomo, Robert
  • Bou, Germán
  • Poza, Margarita
  • González-Bello, Concepción
  • Beceiro Casas, Alejandro
[Abstract] The number of infections caused by Gram-negative pathogens carrying carbapenemases is increasing, and the group of carbapenem-hydrolyzing class D β-lactamases (CHDLs) is especially problematic. Several clinically important CHDLs have been identified in Acinetobacter baumannii, including OXA-23, OXA-24/40, OXA-58, OXA-143, OXA-235, and the chromosomally encoded OXA-51. The selection and dissemination of carbapenem-resistant A. baumannii strains constitutes a serious global threat. Carbapenems have been successfully utilized as last-resort antibiotics for the treatment of multidrug-resistant A. baumannii infections. However, the spread of OXA carbapenemases is compromising the continued use of these antimicrobials. In response to this clinical issue, it is necessary and urgent to design and develop new specific inhibitors with efficacy against these enzymes. The aim of this work was to characterize the inhibitory activity of LN-1-255 (a 6-alkylidene-2-substituted penicillin sulfone) and compare it to that of two established inhibitors (avibactam and tazobactam) against the most relevant enzymes of each group of class D carbapenemases in A. baumannii. The β-lactamase inhibitor LN-1-255 demonstrated excellent microbiological synergy and inhibition kinetics parameters against all tested CHDLs and a significantly higher activity than tazobactam and avibactam. A combination of carbapenems and LN-1-255 was effective against A. baumannii class D carbapenemases. Docking assays confirmed the affinity of LN-1-255 for the active site of these enzymes. LN-1-255 represents a potential new β-lactamase inhibitor that may have a significant role in eradicating infections caused by A. baumannii isolates carrying CHDLs., This work was financially supported by Planes Nacionales de I+D+i 2008-2011/2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014 and REIPI RD16/0016/006), cofinanced by the European Development Regional Fund “A Way to Achieve Europe” and the operative program Intelligent Growth 2014-2020. This work was also supported by the Galician Innovation Agency (IN607A 2016/22) and the ISCIII-General Subdirection of Assessment and Promotion of the Research (PI15/00860 to G.B. and PI14/00059 to M.P. and A.B.). This study was also supported by the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), the Xunta de Galicia (Centro Singular de Investigación de Galicia Accreditation 2016-2019, EDG431G/09), and the European Union (European Regional Development Fund-ERDF) to C.G.-B. J.C.V.-U. and A.B. were financially supported by the Miguel Servet Programme ISCIII-FEDER (CP13/00226). M.M. thanks the Spanish Ministry of Science and Innovation for her FPU fellowship. M.M.G. was financially supported by the grant “Clara Roy” from the Spanish Society of Clinical Microbiology and Infectious Diseases. Research reported in this publication was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AI100560, R01AI063517, and R01AI072219 (to R.A.B.) and T32-GM-7250 to Case Western Reserve University, MLW. This study was supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, award number 1I01BX001974, to R.A.B., and by the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development and the Geriatric Research Education and Clinical Center VISN 10 to R.A.B., Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; EDG431G/09, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI100560, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI063517, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI072219, Case Western Reserve University; T32-GM-7250, Cleveland Department of Veterans Affairs; 1I01BX001974, VA Office of Research and Development and the Geriatric Research Education and Clinical Center; VISN 10
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections

  • Arca-Suárez, Jorge
  • Lasarte-Monterrubio, Cristina
  • Rodiño-Janeiro, Bruno Kotska
  • Cabot, Gabriel
  • Vázquez-Ucha, Juan Carlos
  • Rodríguez-Iglesias, Manuel
  • Galán-Sánchez, Fátima
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Oliver, Antonio
  • Bou, Germán
[Abstract] Background: The development of resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of Pseudomonas aeruginosa infections is concerning. Objectives: Characterization of the mechanisms leading to the development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR P. aeruginosa infections. Methods: Four paired ceftolozane/tazobactam- and ceftazidime/avibactam-susceptible/resistant isolates were evaluated. MICs were determined by broth microdilution. STs, resistance mechanisms and genetic context of β-lactamases were determined by genotypic methods, including WGS. The OXA-10 variants were cloned in PAO1 to assess their impact on resistance. Models for the OXA-10 derivatives were constructed to evaluate the structural impact of the amino acid changes. Results: The same XDR ST253 P. aeruginosa clone was detected in all four cases evaluated. All initial isolates showed OprD deficiency, produced an OXA-10 enzyme and were susceptible to ceftazidime, ceftolozane/tazobactam, ceftazidime/avibactam and colistin. During treatment, the isolates developed resistance to all cephalosporins. Comparative genomic analysis revealed that the evolved resistant isolates had acquired mutations in the OXA-10 enzyme: OXA-14 (Gly157Asp), OXA-794 (Trp154Cys), OXA-795 (ΔPhe153-Trp154) and OXA-824 (Asn143Lys). PAO1 transformants producing the evolved OXA-10 derivatives showed enhanced ceftolozane/tazobactam and ceftazidime/avibactam resistance but decreased meropenem MICs in a PAO1 background. Imipenem/relebactam retained activity against all strains. Homology models revealed important changes in regions adjacent to the active site of the OXA-10 enzyme. The blaOXA-10 gene was plasmid borne and acquired due to transposition of Tn6746 in the pHUPM plasmid scaffold. Conclusions: Modification of OXA-10 is a mechanism involved in the in vivo acquisition of resistance to cephalosporin/β-lactamase inhibitor combinations in P. aeruginosa., This work was supported by MSD through the Investigator Initiated Studies Program, which provided financial support and relebactam. This work was also supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III (ISCIII), through grants PI15/00860 and PI18/00501 to G.B., PI18/00076 to A.O. and P14/00059 and P17/01482 to A.B. Support was also provided by: Planes Nacionales de I + D+i 2013-2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by the European Development Regional Fund ‘A way to achieve Europe’; and the operative Intelligent Growth Program 2014-2020. C.G.-B. acknowledges financial support from the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), the Xunta de Galicia [ED431B 2018/04 and Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/03)] and the European Regional Development Fund (ERDF). J.A.-S. was financially supported by the Fundación Profesor Novoa Santos through a Post-Especialización Grant (2019) and by the Rio Hortega Program (ISCIII, CM19/00219). J.C.V.-U. was financially supported by the pFIS Program (ISCIII, PI17/01482). C.L.-M. was financially supported by an IN606A-2019/029 Grant (Xunta de Galicia).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Rapid detection of KPC-producing Enterobacterales by using a modified Carba NP test with imipenem/relebactam

  • Oviaño, Marina
  • de la Luna Ramírez, Cecilia
  • González-Bardanca, Mónica
  • Candela, Ana
  • Bou, Germán
Brief report, [Abstract] Introduction: Here, we propose a novel modified Carba NP test for detecting KPC-producing Enterobacterales using imipenem/relebactam. Material and methods: The test performance was evaluated in a random selection of 160 previously molecularly characterized clinical isolates carrying the 110 blaKPC, 1 blaGES, 12 blaVIM, 4 blaIMP, 3 blaNDM and 42 blaOXA-48-like genes. The proposed method relies on the detection of imipenem hydrolysis in an imipenem/relebactam antibiotic solution and subsequent visual interpretation by color change. Results: All class A producing Enterobacterales (111/111) were detected using imipenem/relebactam as no visual appreciation of color change was perceived due to a nule hydrolysis of imipenem in the antibiotic solution. Overall, the assay showed 100% sensitivity (111/111) and specificity (69/69) for detecting class A KPC-producing Enterobacterales. Discussion: The biochemical assay provides very reliable results for detecting KPC-producing Enterobacterales, with a turnaround time of less than 1 hour, minimum handling and no specialized equipment required., [Resumen] Introducción. En este manuscrito proponemos un novedoso ensayo basado en el Carba NP test para la detección de Enterobacterales productoras de KPC utilizando imipenem/relebactam. Material y métodos. La evaluación se realizó en una selección aleatoria de 160 aislados clínicos previamente caracterizados molecularmente que portaban los genes 110 blaKPC, 1 blaGES, 12 blaVIM, 4 blaIMP, 3 blaNDM y 42 blaOXA-48-like. El método propuesto se basa en la detección de la hidrólisis de imipenem en una solución de imipenem/relebactam y posteriormente su interpretación mediante un cambio de color. Resultados. El ensayo tiene una sensibilidad (111/111) y una especificidad (69/69) del 100% para detectar Enterobacterales productoras de KPC, de clase A. Discusión. Este ensayo bioquímico proporciona resultados muy fiables para la detección de Enterobacterales productoras de KPC, con un tiempo de respuesta inferior a 1 h, además de una manipulación mínima y sin necesidad de ningún equipamiento especializado., The results of this work have been funded by the Projects N° PI15/00860 and PI18/00501, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research – European Regional Development Fund (FEDER) “A way of making Europe”.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

In-Depth Analysis of the Role of the Acinetobactin Cluster in the Virulence of Acinetobacter baumannii

  • Conde-Pérez, Kelly
  • Vázquez-Ucha, Juan Carlos
  • Álvarez-Fraga, Laura
  • Ageitos, Lucía
  • Rumbo-Feal, Soraya
  • Martínez Guitián, Marta
  • Trigo Tasende, Noelia
  • Rodríguez, Jaime
  • Bou, Germán
  • Jiménez, Carlos
  • Beceiro Casas, Alejandro
  • Poza, Margarita
[Abstract] Acinetobacter baumannii is a multidrug-resistant pathogen that represents a serious threat to global health. A. baumannii possesses a wide range of virulence factors that contribute to the bacterial pathogenicity. Among them, the siderophore acinetobactin is one of the most important, being essential for the development of the infection. In this study we performed an in-depth analysis of the acinetobactin cluster in the strain A. baumannii ATCC 17978. For this purpose, nineteen individual isogenic mutant strains were generated, and further phenotypical analysis were performed. Individual mutants lacking the biosynthetic genes entA, basG, basC, basD, and basB showed a significant loss in virulence, due to the disruption in the acinetobactin production. Similarly, the gene bauA, coding for the acinetobactin receptor, was also found to be crucial for the bacterial pathogenesis. In addition, the analysis of the ΔbasJ/ΔfbsB double mutant strain demonstrated the high level of genetic redundancy between siderophores where the role of specific genes of the acinetobactin cluster can be fulfilled by their fimsbactin redundant genes. Overall, this study highlights the essential role of entA, basG, basC, basD, basB and bauA in the pathogenicity of A. baumannii and provides potential therapeutic targets for the design of new antivirulence agents against this microorganism., This work was funded by Projects PI15/00860 awarded to GB and PI17/01482 to AB and MP, all within in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII – General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by project IN607A 2016/22 (GAIN- Agencia Gallega de Innovación – Consellería de Economía, Emprego e Industria) awarded to GB. This work was also supported by Planes Nacionales de I + D + i 2008–2011/2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. This work was also supported by Grant RTI2018-093634-B-C22 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, co-funded by the FEDER Programme from the European Union and Xunta de Galicia for the support of Grant ED431E 2018/03 for CICA-INIBIC strategic and the initiative “Seed Projects 2019–2020.” JV-U was financially supported by the ISCIII project FI18/00315, LÁ-F by the ISCIII project PI14/00059 and the IN606B-2018/011, MM-G was financially supported by the Grant Clara Roy (SEIMC, Spanish Society of Clinical Microbiology and Infectious Diseases), KC-P by IN607A 2016/22 and AECC (Asociación Española Contra el Cáncer) predoctoral fellowship and LA by Xunta de Galicia co-funded with the European Social Fund (FSE) of the European Union (ED481A-2019/081), Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606B-2018/011, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED481A-2019/081
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing

  • Arca-Suárez, Jorge
  • Rodiño-Janeiro, Bruno Kotska
  • Pérez Gómez, Astrid
  • Guijarro-Sánchez, Paula
  • Vázquez-Ucha, Juan Carlos
  • Cruz, Fernando
  • Gómez-Garrido, Jéssica
  • Alioto, Tyler S.
  • Álvarez-Tejado, Miguel
  • Gut, Marta
  • Gut, Ivo
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • Bou, Germán
Comparative study, [Abstract] The emergence of 16S rRNA methyltransferases (RMTs) in Gram-negative pathogens bearing other clinically relevant resistance mechanisms, such as carbapenemase-producing Enterobacterales (CPE), is becoming an alarming concern. We investigated the prevalence, antimicrobial susceptibility, resistance mechanisms, molecular epidemiology and genetic support of RMTs in CPE isolates from Spain. This study included a collection of 468 CPE isolates recovered during 2018 from 32 participating Spanish hospitals. MICs were determined using the broth microdilution method, the agar dilution method (fosfomycin) or MIC gradient strips (plazomicin). All isolates were subjected to hybrid whole-genome sequencing (WGS). Sequence types (STs), core genome phylogenetic relatedness, horizontally acquired resistance mechanisms, plasmid analysis and the genetic environment of RMTs were determined in silico from WGS data in all RMT-positive isolates. Among the 468 CPE isolates evaluated, 24 isolates (5.1%) recovered from nine different hospitals spanning five Spanish regions showed resistance to all aminoglycosides and were positive for an RMT (21 RmtF, 2 ArmA and 1 RmtC). All RMT-producers showed high-level resistance to all aminoglycosides, including plazomicin, and in most cases exhibited an extensively drug-resistant susceptibility profile. The RMT-positive isolates showed low genetic diversity and were global clones of Klebsiella pneumoniae (ST147, ST101, ST395) and Enterobacter cloacae (ST93) bearing blaOXA-48, blaNDM-1 or blaVIM-1 carbapenemase genes. RMTs were harboured in five different multidrug resistance plasmids and linked to efficient mobile genetic elements. Our findings highlight that RMTs are emerging among clinical CPE isolates from Spain and their spread should be monitored to preserve the future clinical utility of aminoglycosides and plazomicin., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI15/00860 and PI18/00501 to GB and P17/01482 to AB. MG and IG acknowledge the support of the MEIC through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and co-financing with the European Regional Development Fund [MINECO/FEDER, BIO2015-71792-P]. MG and IG also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d'Empresa i Coneixement and the CERCA Programme. Support was also provided by Planes Nacionales de I+D+i 2013–2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/006] co-financed by the European Regional Development Fund ‘A Way to Achieve Europe’, and the operative Intelligent Growth program 2014–2020. JAS was financially supported by the Fundacion Profesor Novoa Santos through a Post-especialización grant and by the Rio Hortega program [ISCIII-SERGAS, CM19/00219]. MO was financially supported by the Juan Rodés program [ISCIII-SERGAS, JR18/00006]. JCVU was financially supported by the pFIS program [ISCIII, PI17/01482].
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

  • Arca-Suárez, Jorge
  • Vázquez-Ucha, Juan Carlos
  • Fraile-Ribot, Pablo Arturo
  • Lence, Emilio
  • Cabot, Gabriel
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Rodríguez-Iglesias, Manuel
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Galán-Sánchez, Fátima
  • Oliver, Antonio
  • Bou, Germán
[Abstract] Background: Pseudomonas aeruginosa may develop resistance to novel cephalosporin/β-lactamase inhibitor combinations during therapy through the acquisition of structural mutations in AmpC. Objectives: To describe the molecular and biochemical mechanisms involved in the development of resistance to ceftolozane/tazobactam in vivo through the selection and overproduction of a novel AmpC variant, designated PDC-315. Methods: Paired susceptible/resistant isolates obtained before and during ceftolozane/tazobactam treatment were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. Characterization of the novel PDC-315 variant was performed through genotypic and biochemical studies. The effects at the molecular level of the Asp245Asn change were analysed by molecular dynamics simulations using Amber. Results: WGS identified mutations leading to modification (Asp245Asn) and overproduction of AmpC. Susceptibility testing revealed that PAOΔC producing PDC-315 displayed increased MICs of ceftolozane/tazobactam, decreased MICs of piperacillin/tazobactam and imipenem and similar susceptibility to ceftazidime/avibactam compared with WT PDCs. The catalytic efficiency of PDC-315 for ceftolozane was 10-fold higher in relation to the WT PDCs, but 3.5- and 5-fold lower for piperacillin and imipenem. IC50 values indicated strong inhibition of PDC-315 by avibactam, but resistance to cloxacillin inhibition. Analysis at the atomic level explained that the particular behaviour of PDC-315 is linked to conformational changes in the H10 helix that favour the approximation of key catalytic residues to the active site. Conclusions: We deciphered the precise mechanisms that led to the in vivo emergence of resistance to ceftolozane/tazobactam in P. aeruginosa through the selection of the novel PDC-315 enzyme. The characterization of this new variant expands our knowledge about AmpC-mediated resistance to cephalosporin/β-lactamase inhibitors in P. aeruginosa., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI15/00860 and PI18/00501 to G.B., PI18/00076 to A.O., and P14/00059 and P17/01482 to A.B. Support was also provided by Planes Nacionales de I + D+i 2013–2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by the European Development Regional Fund ‘A way to achieve Europe’; and the operative Intelligent Growth program 2014–2020. C.G-B. acknowledges financial support from the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R, C.G-B.), the Xunta de Galicia [ED431B 2018/04 and Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/03)], and the European Regional Development Fund (ERDF). E.L. thanks the Xunta de Galicia for his postdoctoral fellowship. J.A-S. was financially supported by the Fundación Profesor Novoa Santos through a Post-especialización Grant (2019) and by the Rio Hortega program (ISCIII, CM19/00219). J.C.V-U. was financially supported by the pFIS program (ISCIII, PI17/01482). M.M-G. was financially supported by a Clara Roy grant (SEIMC) and C.L-M. by IN606A-2019/029.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the rapid detection of antimicrobial resistance mechanisms and beyond

  • Oviaño, Marina
  • Bou, Germán
Review, [Abstract] Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has been successfully applied in recent years for first-line identification of pathogens in clinical microbiology because it is simple to use, rapid, and accurate and has economic benefits in hospital management. The range of clinical applications of MALDI-TOF MS for bacterial isolates is increasing constantly, from species identification to the two most promising applications in the near future: detection of antimicrobial resistance and strain typing for epidemiological studies. The aim of this review is to outline the contribution of previous MALDI-TOF MS studies in relation to detection of antimicrobial resistance and to discuss potential future challenges in this field. Three main approaches are ready (or almost ready) for clinical use, including the detection of antibiotic modifications due to the enzymatic activity of bacteria, the detection of antimicrobial resistance by analysis of the peak patterns of bacteria or mass peak profiles, and the detection of resistance by semiquantification of bacterial growth in the presence of a given antibiotic. This review provides an expert guide for MALDI-TOF MS users to new approaches in the field of antimicrobial resistance detection, especially possible applications as a routine diagnostic tool in microbiology laboratories., This work was supported by the Fondo de Investigación Sanitaria (grant PI15/00860 to G.B.), integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII). The results of this work have been funded by the Spanish Network of Research in Infectious Diseases (REIPI) (grant RD16/0016/0006), integrated in the National Plan for Scientific Research, Development, and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) A Way of Making Europe.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

In Vitro and In Vivo Assessment of the Efficacy of Bromoageliferin, an Alkaloid Isolated from the Sponge Agelas dilatata, against Pseudomonas aeruginosa

  • Pech-Puch, Dawrin
  • Pérez Povedano, Mar Anabel
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Vázquez-Ucha, Juan Carlos
  • Bou, Germán
  • Rodríguez, Jaime
  • Beceiro Casas, Alejandro
  • Jiménez, Carlos
[Abstract] The pyrrole-imidazoles, a group of alkaloids commonly found in marine sponges belonging to the genus Agelas, display a wide range of biological activities. Herein, we report the first chemical study of the secondary metabolites of the sponge A. dilatata from the coastal area of the Yucatan Peninsula (Mexico). In this study, we isolated eight known alkaloids from an organic extract of the sponge. We used NMR and MS analysis and comparison with existing databases to characterize the alkaloids: ageliferin (1), bromoageliferin (2), dibromoageliferin (3), sceptrin (4), nakamuric acid (5), 4-bromo-1H-pyrrole-2-carboxylic acid (6), 4,5-dibromopyrrole-2-carboxylic acid (7) and 3,7-dimethylisoguanine (8). We also evaluated, for the first time, the activity of these alkaloids against the most problematic multidrug-resistant (MDR) pathogens, i.e., the Gram-negative bacteria Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii. Bromoageliferin (2) displayed significant activity against P. aeruginosa. Comparison of the antibacterial activity of ageliferins 1–3 (of similar structure) against P. aeruginosa revealed some relationship between structure and activity. Furthermore, in in vitro assays, 2 inhibited growth and biofilm production in clinical strains of P. aeruginosa. Moreover, 2 increased the survival time in an in vivo Galleria mellonella model of infection. The findings confirm bromoageliferin (2) as a potential lead for designing new antibacterial drugs., This work was supported by Grants RTI2018-093634-B-C22 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, both co-funded by the FEDER Programme from the European Union and BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme INTERREG V A of Spain-Portugal (POCTEP). The study was also funded by projects GRC2018/039 and Agrupación Estratégica CICA-INIBIC ED431E 2018/03 (Consellería de Educación, Universidades e Formación Profesional) from the Xunta de Galicia (autonomous government of the region). This work was also funded by Projects PI17/01482 awarded to AB and PI15/00860 to GB, all within in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” and operative program Intelligent Growth 2014-2020. The study was also funded by project IN607A 2016/22 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) awarded to GB. D.P.-P. received a fellowship from the program National Council of Science and Technology (CONACYT) of Mexico and the Secretariat of Research, Innovation and Higher Education (SIIES) of Yucatan. Mexico and the Secretariat of Research, Innovation and Higher Education (SIIES) of Yucatan. JCVU was financially supported by the pFIS Program (FI18/00315), MMG by a Clara Roy grant (SEIMC) and CLM by IN606A-2019/029, Xunta de Galicia; GRC2018/039, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; IN606A-2019/029
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Building-Scale Wastewater-Based Epidemiology for SARS-CoV-2 Surveillance at Nursing Homes in A Coruña, Spain

  • Trigo Tasende, Noelia
  • Vallejo, J. A.
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • Nasser-Ali, Mohammed
  • Tarrío-Saavedra, Javier
  • Barbeito, Inés
  • Cao, Ricardo
  • Ladra, Susana
  • Bou, Germán
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract] Wastewater-based epidemiology (WBE) has become an effective tool in the surveillance of infectious diseases such as COVID-19. In this work, we performed a brief study of monitoring the SARS-CoV-2 viral load in wastewater from six nursing homes located in the metropolitan area of A Coruña (Spain) between December 2020 and March 2021. The main objective was to detect SARSCoV- 2 outbreaks among residents and study the efficacy of the vaccination campaign. SARS-CoV-2 viral load (RNA copies per L of wastewater) was determined by reverse-transcription quantitative PCR (RT-qPCR) using the quantification cycle (Cq) values for the nucleocapsid (N) gene. Our results showed that the increase in viral load preceded the increase in clinical cases, favoring an early warning system that detects COVID-19 outbreaks in advance, making it possible to contain and stop the transmission of the virus among residents. In addition, the efficacy of the new COVID-19 vaccines was evidenced, since after the vaccination campaign in nursing homes in A Coruña, it was observed that many residents did not present any symptoms of the disease, although they excreted high amounts of virus in their feces. WBE is a cost-effective strategy that should be implemented in all cities to prevent new emerging diseases or future pandemic threats., EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, EDAR Bens S.A.; INV148721, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2021/53, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; COV20/00604, Funding for open access charge: Universidade da Coruña/CISUG. This work was mainly supported by the grant INV00821 from Consellería de Política Social (Xunta de Galicia, Spain) to M.P. The team was also supported by EDAR Bens S.A., A Coruña, Spain (grant references INV04020, INV12120, INV05921, and INV148721 to M.P.), by the National Plan for Scientific Research, Development and Technological Innovation funded by the Institute of Health Carlos III (ISCIII), Spain—General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant references PI15/00860 to G.B., PI17/01482 and PI20/00413 to M.P.], by the Galician Innovation Agency (GAIN) (Xunta de Galicia, Spain) [grant references IN607A 2016/22 to G.B., ED431C-2016/015 and ED431C-2020/14 to R.C., ED431C 2021/53 to S.L., and ED431G 2019/01 and COV20/00604 to R.C. and S.L., by the Ministry of Economic Affairs and Digital Transformation (MINECO), Spain (grant references MTM2017-82724-R to R.C.), by the Spanish Network of Research in Infectious Diseases (CIBERINFEC, ISCIII, reference CB21/13/00055), and by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 871029. S.R.-F. was financially supported by REIPI RD16/0016/006, K.C.-P. by IN607A 2016/22 and the Spanish Association against Cancer (AECC), and J.A.V. by IN607A 2016/22.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Occurrence of the p019 gene in the blaKPC-harboring plasmids: adverse clinical impact for direct tracking of KPC-producing Klebsiella pneumoniae by matrix-assisted laser desorption ionization-time of flight mass spectrometry

  • Gato, Eva
  • Constanso-Conde, Ignacio
  • Rodiño-Janeiro, Bruno Kotska
  • Guijarro-Sánchez, Paula
  • Alioto, Tyler S.
  • Arroyo, Manuel J.
  • Méndez, Gema
  • Mancera, Luis
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Bou, Germán
  • Oviaño, Marina
[Abstract] Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has recently been used for the direct detection of KPC-producing isolates by analysis of the 11,109 Da mass peak representing the P019 protein. In this study, we evaluate the presence of the 11,109 Da mass peak in a collection of 435 unduplicated Klebsiella pneumoniae clinical isolates. The prevalence of the P019 peak in the blaKPC K. pneumoniae isolates was 49.2% (32/65). The 11,109 Da mass peak was not observed in any of the other carbapenemase (319) or noncarbapenemase producers (116). Computational analysis of the presence of the p019 gene was performed in the aforementioned carbapenemase-producing K. pneumoniae isolates fully characterized by whole-genome sequencing (WGS) and in a further collection of 1,649 K. pneumoniae genomes included in EuSCAPE. Herein, we have demonstrated that the p019 gene is not exclusively linked to the pKpQil plasmid but that it is present in the following plasmids: IncFIB(K)/IncFII(K)/ColRNAI, IncFIB(pQil), IncFIB(pQil)/ColRNAI, IncFIB(pQil)/IncFII(K), IncFIB(K)/IncFII(K), and IncX3. In addition, we have proven the independent movement of the Tn4401 and the ISKpn31, of which the p019 gene is a component. The absence of the p019 gene was obvious in Col440I, Col(pHAD28), IncFIB(K)/IncX3/IncFII(K), and IncFIB(K)/IncFII(K) plasmids. In addition, we also observed another plasmid in which neither Tn4401 nor ISKpn31 was found, IncP6. In the EuSCAPE, the occurrence of p019 varied from 0% to 100% among the different geographical locations. The adverse clinical impact of the diminished prevalence of the p019 gene within the plasmid encoding KPC-producing Klebsiella pneumoniae puts forward the need for reconsideration when applying this technique in a clinical setting., This study was supported by funding awarded to M.O. throughout the competitive research call 2019 of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). The research was also funded by the Fondo de Investigación Sanitaria (grant numbers PI15/00860, PI18/00860 to G.B.) integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII) and by the Spanish Network of Research in Infectious Diseases (REIPI), number RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation2013 to 2016 and funded by the ISCIII- General Subdirection of Assessment and Promotion of the Research – European Regional Development Fund (FEDER) “A way of making Europe.” M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006) and E.G. was financially supported by the research call 2019 of the SEIMC. Clover Biosoft has received funding from the European Union’s Horizon H2020 research and innovation program under grant agreement number 868365.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Increased antimicrobial resistance in a novel CMY-54 AmpC-type enzyme with a GluLeu217-218 insertion in the Ω-loop

  • Pérez-Llarena, Francisco J.
  • Vázquez-Ucha, Juan Carlos
  • Kerff, Frédéric
  • Zamorano, Laura
  • Miró, Elisenda
  • Póvoa Cabral, María
  • Fleites, Ana
  • Lantero, Marta
  • Martínez-Martínez, Luis
  • Oliver, Antonio
  • Galleni, Moreno
  • Navarro, Ferrán
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] During a Spanish surveillance study, a natural variant of a CMY-type β-lactamase related to CMY-2 with a GluLeu217-218 insertion in the Ω-loop (designated CMY-54) was found to increase the minimum inhibitory concentractions to β-lactams in a clinical strain of Escherichia coli. The aim of this study was to characterize CMY-54 by genetic, microbiological, and biochemical analysis. The blaCMY-54 gene is encoded by a plasmid of around 100 kb that hybridizes with K and FIB probes. The genetic context of blaCMY-54 and blaCMY-2 genes was found to be very similar. E. coli expressing CMY-54 under isogenic conditions showed a clear fourfold to eightfold increase in MICs to penicillins, cefotaxime, ceftazidime, and aztreonam compared with CMY-2. The catalytic efficiencies of pure CMY-2 and CMY-54 proteins correlated with their microbiological parameters. CMY-2 protein was more resistant to thermal denaturation than CMY-54, indicating that the Ω-loop of CMY-54 may be wider and more relaxed and probably enables better accommodation of these antimicrobials. Otherwise, the higher stabilization of CMY-2 may induce a slight reduction of the dynamics of this enzyme and primarily affect the hydrolysis of some of the bulkiest antibiotics. In summary, the GluLeu217-218 insertion observed in CMY-54 compared to CMY-2 produces a β-lactamase with a distinctive catalytic efficacy for β-lactam antimicrobials likely caused by an increased flexibility slightly affecting the active site shape, highlighting the relevance of single mutations on the hydrolytic spectrum in class C β-lactamases., This work was funded by the European Community, FP7, ID:278232 (MagicBullet) and by the Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0006) – cofinanced by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020. Additional funding was provided by the Fondo de Investigación Sanitaria (grants PI12/00552, PI14/00059, and PI15/00860) and by the ISCIII: CP13/00226. F.K. is a research associate from the FRS-FNRS (Belgium).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Challenging antimicrobial susceptibility and evolution of resistance (oxa-681) during treatment of a long-term nosocomial infection caused by a pseudomonas aeruginosa ST175 Clone

  • Arca-Suárez, Jorge
  • Fraile-Ribot, Pablo Arturo
  • Vázquez-Ucha, Juan Carlos
  • Cabot, Gabriel
  • Martínez Guitián, Marta
  • Lence, Emilio
  • González-Bello, Concepción
  • Beceiro Casas, Alejandro
  • Rodríguez-Iglesias, Manuel
  • Galán, Fátima
  • Bou, Germán
  • Oliver, Antonio
Case report, [Abstract] Selection of extended-spectrum mutations in narrow-spectrum oxacillinases (e.g., OXA-2 and OXA-10) is an emerging mechanism for development of in vivo resistance to ceftolozane-tazobactam and ceftazidime-avibactam in Pseudomonas aeruginosa Detection of these challenging enzymes therefore seems essential to prevent clinical failure, but the complex phenotypic plasticity exhibited by this species may often lead to their underestimation. The underlying resistance mechanisms of two sequence type 175 (ST175) P. aeruginosa isolates showing multidrug-resistant phenotypes and recovered at early and late stages of a long-term nosocomial infection were evaluated. Whole-genome sequencing (WGS) was used to investigate resistance genomics, whereas molecular and biochemical methods were used for characterization of a novel extended-spectrum OXA-2 variant selected during therapy. The metallo-β-lactamase blaVIM-20 and the narrow-spectrum oxacillinase blaOXA-2 were present in both isolates, although they differed by an inactivating mutation in the mexB subunit, present only in the early isolate, and in a mutation in the blaOXA-2 β-lactamase, present only in the final isolate. The new OXA-2 variant, designated OXA-681, conferred elevated MICs of the novel cephalosporin-β-lactamase inhibitor combinations in a PAO1 background. Compared to OXA-2, kinetic parameters of the OXA-681 enzyme revealed a substantial increase in the hydrolysis of cephalosporins, including ceftolozane. We describe the emergence of the novel variant OXA-681 during treatment of a nosocomial infection caused by a Pseudomonas aeruginosa ST175 high-risk clone. The ability of OXA-681 to confer cross-resistance to ceftolozane-tazobactam and ceftazidime-avibactam together with the complex antimicrobial resistance profiles exhibited by the clinical strains harboring this new enzyme argue for maintaining active surveillance on emerging broad-spectrum resistance in P. aeruginosa., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI1800076 to A.O., PI15/00860 and PI18/00501 to G.B., and P14/00059 and P17/01482 to A.B. and through grants from the Spanish Ministry of Economy and Competitiveness (SAF2016-75638-R) and the Xunta de Galicia (ED431G/09) to C.G.-B. This work was also supported by the European Regional Development Fund A Way To Achieve Europe ERDF, through the Spanish Network for Research in Infectious Diseases (RD16/0016). J.C.V.-U. was financially supported by the pFIS program (ISCIII, PI17/01482), and M.M.-G. was financially supported by a Clara Roy grant (SEIMC).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii

  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Maneiro Rey, María
  • Conde-Pérez, Kelly
  • Álvarez-Fraga, Laura
  • Torrens Ribot, Gabriel
  • Oliver, Antonio
  • Buynak, John
  • Bonomo, Robert
  • Bou, Germán
  • González-Bello, Concepción
  • Poza, Margarita
  • Beceiro Casas, Alejandro
[Abstract] The carbapenem-hydrolyzing class D β-lactamases (CHDLs) are the main mechanism of carbapenem resistance in Acinetobacter baumannii. CHDLs are not effectively inactivated by clinically available β-lactam-type inhibitors. We have previously described the in vitro efficacy of the inhibitor LN-1-255 in combination with carbapenems. The aim of this study was to compare the efficacy of LN-1-255 with that of imipenem in murine pneumonia using A. baumannii strains carrying their most extended carbapenemases, OXA-23 and OXA-24/40. The blaOXA-23 and blaOXA-24/40 genes were cloned into the carbapenem-susceptible A. baumannii ATCC 17978 strain. Clinical isolates Ab1 and JC12/04, producing the enzymes OXA-23 and OXA-24/40, respectively, were used in the study. Pharmacokinetic (PK) parameters were determined. An experimental pneumonia model was used to evaluate the efficacy of the combined imipenem–LN-1-255 therapy. MICs of imipenem decreased between 32- and 128-fold in the presence of LN-1-255. Intramuscular treatment with imipenem–LN-1-255 (30/50 mg/kg) decreased the bacterial burden by (i) 4 and 1.7 log10 CFU/g lung in the infection with the ATCC 17978-OXA-23 and Ab1 strains, respectively, and by (ii) 2.5 and 4.5 log10 CFU/g lung in the infection produced by the ATCC 17978-OXA-24/40 and the JC12/04 strains, respectively. In all assays, combined therapy offered higher protection against pneumonia than that provided by monotherapy. No toxicity was observed in treated mice. Imipenem treatment combined with LN-1-255 treatment significantly reduced the severity of infection by carbapenem-resistant A. baumannii strains carrying CHDLs. Preclinical assays demonstrated the potential of LN-1-255 and imipenem therapy as a new antibacterial treatment., This work has been funded by projects PI15/00860 to G.B., CP13/00226 to A.B., and P14/00059 and PI17/01482 to M.P. and A.B., all of which were integrated into the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe,” The study was also funded by project IN607A 2016/22 (Consellería de Cultura, Educación e Ordenación Universitaria) to G.B. This study was also funded by the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), Xunta de Galicia (Centro Singular de Investigación de Galicia accreditation 2016 to 2019, ED431G/09), and by the European Regional Development Fund (ERDF) to C.G.-B. This work was also supported by Planes Nacionales de I+D+i 2008-2011/2013-2016 and by Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006), cofinanced by the European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. Also, this study was supported in part by funds from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (USA) under award numbers R01AI063517, R01AI072219, and R01AI100560, by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program award 1I01BX001974, and by the Geriatric Research Education and Clinical Center VISN 10 to R.A.B. J.D.B. acknowledges support from the National Institutes of Allergy and Infectious Diseases under award number R15AI142699. J.C.V.-U. was financially supported by the Miguel Servet Programme (CP13/00226; ISCIII, Spain) and by Consellería de Cultura, Educación e Ordenación Universitaria (IN607A 2016/22), and M.M.-G. was financially supported by a Clara Roy grant (Spanish Society of Clinical Microbiology and Infectious Diseases [SEIMC])., Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431G/09, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI063517, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI072219, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI100560, Estados Unidos. National Institutes of Allergy and Infectious Diseases; R15AI142699
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

The FhaB/FhaC two-partner secretion system is involved in adhesion of Acinetobacter baumannii AbH12O-A2 strain

  • Pérez Gómez, Astrid
  • Merino, María Cecilia
  • Rumbo-Feal, Soraya
  • Álvarez-Fraga, Laura
  • Vallejo, J. A.
  • Beceiro Casas, Alejandro
  • Ohneck, Emily J.
  • Mateos, Jesús
  • Fernández-Puente, Patricia
  • Actis, Luis
  • Poza, Margarita
  • Bou, Germán
[Abstract] Acinetobacter baumannii is a hospital-acquired pathogen that shows an extraordinary capacity to stay in the hospital environment. Adherence of the bacteria to eukaryotic cells or to abiotic surfaces is the first step for establishing an infection. The A. baumannii strain AbH12O-A2 showed an exceptional ability to adhere to A549 epithelial cells. The AbFhaB/FhaC 2-partner secretion (TPS) system involved in adhesion was discovered after the screening of the recently determined A. baumannii AbH12O-A2 strain genome (CP009534.1). The AbFhaB is a large exoprotein which transport to the bacterial surface is mediated by the AbFhaC protein. In the present study, the role of this TPS system in the AbH12O-A2 adherence phenotype was investigated. The functional inactivation of this 2-partner secretion system was addressed by analyzing the outer membrane vesicles (OMV) proteomic profile from the wild-type strain and its derivative mutant AbH12O-A2ΔfhaC demonstrating that AbFhaB is no longer detected in the absence of AbFhaC. Scanning electron microscopy (SEM) and adhesion experiments demonstrated that inactivation of the AbFhaB/FhaC system significantly decreases bacterial attachment to A549 alveolar epithelial cells. Moreover, it has been demonstrated that this 2-partner secretion system is involved in fibronectin-mediated adherence of the A. baumannii AbH12O-A2 isolate. Finally, we report that the AbFhaB/FhaC system is involved in virulence when tested using invertebrate and vertebrate hosts. These data suggest the potential role that this AbFhaB/FhaC secretion system could play in the pathobiology of A. baumannii., This work has been funded by Projects PI12/00552 and PI15/00860 to GB, PI11/01034 to MP, CP13/00226 to AB, and P14/000059 to MP and AB, all integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII - General Subdirection of Assessment and Promotion of the Research – European Regional Development Fund (FEDER) “A way of making Europe.” Miami University Research Funds from the department of Microbiology supported this work. We also want to thank the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014 to GB), co-financed by the European Development Regional Fund (EDRF) “A Way to Achieve Europe, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad as well as Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). A.P. was financially supported by the Galician Plan for Research, Innovation and Growth (I2C Plan 2012–2016). J. A. Vallejo was financially supported by the Sara Borrell Program (ISCIII, Spain CD13/00373). S. Rumbo-Feal was financially supported by the Agustí Pumarola Grant (Societat Catalana de Malalties Infeccioses i Microbiologia Clínica, SCMIMC) and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Finally, we thank Chua Kim Lee (University of Singapore) for providing pMo130-TelR.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales

  • Vázquez-Ucha, Juan Carlos
  • Seoane-Estévez, Alejandro
  • Rodiño-Janeiro, Bruno Kotska
  • González-Bardanca, Mónica
  • Conde-Pérez, Kelly
  • Martínez Guitián, Marta
  • Álvarez-Fraga, Laura
  • Arca-Suárez, Jorge
  • Lasarte-Monterrubio, Cristina
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Background: Imipenem/relebactam is a novel carbapenem/β-lactamase inhibitor combination, developed to act against carbapenemase-producing Enterobacterales (CPE). Objectives: To assess the in vitro activity of imipenem/relebactam against a Spanish nationwide collection of CPE by testing the susceptibility of these isolates to 16 widely used antimicrobials and to determine the underlying β-lactam resistance mechanisms involved and the molecular epidemiology of carbapenemases in Spain. Materials and methods: Clinical CPE isolates (n = 401) collected for 2 months from 24 hospitals in Spain were tested. MIC50, MIC90 and susceptibility/resistance rates were interpreted in accordance with the EUCAST guidelines. β-Lactam resistance mechanisms and molecular epidemiology were characterized by WGS. Results: For all isolates, high rates of susceptibility to colistin (86.5%; MIC50/90 = 0.12/8 mg/L), imipenem/relebactam (85.8%; MIC50/90 = 0.5/4 mg/L) and ceftazidime/avibactam (83.8%, MIC50/90 = 1/≥256 mg/L) were observed. The subgroups of isolates producing OXA-48-like (n = 305, 75.1%) and KPC-like enzymes (n = 44, 10.8%) were highly susceptible to ceftazidime/avibactam (97.7%, MIC50/90 = 1/2 mg/L) and imipenem/relebactam (100.0%, MIC50/90 = ≤0.25/1 mg/L), respectively. The most widely disseminated high-risk clones of carbapenemase-producing Klebsiella pneumoniae across Spain were found to be ST11, ST147, ST392 and ST15 (mostly associated with OXA-48) and ST258/512 (in all cases producing KPC). Conclusions: Imipenem/relebactam, colistin and ceftazidime/avibactam were the most active antimicrobials against all CPEs. Imipenem/relebactam is a valuable addition to the antimicrobial arsenal used in the fight against CPE, particularly against KPC-producing isolates, which in all cases were susceptible to this combination., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI15/00860, PI18/00860 to G.B. and PI17/01482, PI20/01212 to A.B.) integrated in the Plan Nacional de I + D and funded by the Instituto de Salud Carlos III (ISCIII). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII—General Subdirection of Assessment and Promotion of the Research—European Regional Development Fund (FEDER) ‘A way of making Europe’.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Syzygium aromaticum (clove) and Thymus zygis (thyme) essential oils increase susceptibility to colistin in the nosocomial pathogens Acinetobacter baumannii and Klebsiella pneumoniae

  • Poza, Margarita
  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Conde-Pérez, Kelly
  • Arca-Suárez, Jorge
  • Álvarez-Fraga, Laura
  • Pérez Gómez, Astrid
  • Crecente-Campo, José
  • Alonso, María J.
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] The discovery of new antibiotics that are effective against Acinetobacter baumannii and Enterobacteralesis a research priority. Several essential oils (EOs) have displayed some antimicrobial activity and could potentially act as antibiotic adjuvants. Research in this area aims to develop new therapeutic alternatives to treat infections caused by these pathogens. MICs of different EOs were determined against A. baumannii and Klebsiella pneumoniae. Combined disk diffusion tests and checkerboard assays were used to study the synergy between the EOs and antibiotics. The fractional inhibitory concentration index (FICindex) was calculated in order to categorize the interaction. Time-kill assays were also performed. The EOs that displayed the highest levels of antimicrobial activity were clove (Syzygium aromaticum L.) and thyme (Thymus zygis L.). Combined disk diffusion tests and checkerboard assays revealed synergy between these EOs and colistin. Addition of either clove or thyme EO decreased the MIC of colistin by 8- to 64-fold and 8- to 128-fold in the colistin-resistant A. baumannii and K. pneumoniae strains, respectively (FICindex ≤ 0.5, synergy). MICs were also reduced in the colistin-susceptible strains. Time-kill assays also indicated the strong activity of the combined therapy. In summary, the use of clove or thyme EO in combination with colistin could improve the efficacy of the antibiotic and significantly reduce the concentrations needed to inhibit growth of A. baumannii and K. pneumoniae., Funding: This study was funded by projects IN607A 2016/22 (GAIN), PI15/00860, PI18/00501 and REIPI RD16/0016/006 (co-financed by the European Development Regional Fund "A way to achieve Europe" and the operative Intelligent Growth program 2014-2020) awarded to GB, PI14/00059 and PI17/01482 awarded to AB and MP (Instituto de Salud Carlos III). JCVU was financially supported the pFIS Programme (FI18/00315, ISCIII), MMG by a Clara Roy grant (SEIMC), KCP by IN607A 2016/22 (GAIN), CLM by IN606A-2019/029 (GAIN) and JAS by the Rio Hortega program (CM19/00219, ISCIII) and the FPNS (post-specialization grant). Acknowledgements: We thank Dr J.D. Boyce for the kind gift of ATCC19606ΔlpxC. We also thank Dr S. Pournaras for the kind gift of AB248 and AB249.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Rapid detection of the plasmid-mediated quinolone resistance determinant AAC(6')-Ib-cr in Enterobacteriaceae by MALDI-TOF MS analysis

  • Oviaño, Marina
  • Rodríguez-Martínez, José Manuel
  • Pascual, Álvaro
  • Bou, Germán
[Abstract] Objectives: Rapid detection of the plasmid-mediated quinolone resistance determinant AAC(6')-Ib-cr in Enterobacteriaceae by measuring acetyltransferase activity against fluoroquinolones by MALDI-TOF MS analysis. Methods: The presence of the AAC(6')-Ib-cr enzyme was determined by MS by measuring the acetyltransferase activity of a collection of 81 isogenic Escherichia coli control strains [10 carrying the AAC(6')-Ib-cr enzyme during exposure to ciprofloxacin, norfloxacin and levofloxacin] and further analysis of 36 clinical isolates [25 carrying the AAC(6')-Ib-cr enzyme in addition to different combinations of quinolone resistance mechanisms]. The effect of acetylation yields an increase of 43 Da in the mass of ciprofloxacin and norfloxacin, but not of levofloxacin, that can be observed by visual inspection of the mass peaks in the spectra. Results: Based on the characteristic peak pattern for the acetylated and non-acetylated forms of ciprofloxacin and norfloxacin, a clear differentiation between AAC(6')-Ib-cr-producing isolates and non-AAC(6')-Ib-cr-producing isolates was detected after an incubation time of 30 min, both in the isogenic control strains and in the clinical isolates. Levofloxacin was found intact. A 100% agreement was found between the MALDI-TOF-MS-based assay and the results of the molecular characterization of the tested isolates. Conclusions: MALDI-TOF MS is an outstanding method for detection of the AAC(6')-Ib-cr enzyme in clinical samples. The method is easy to perform and not time consuming, as analytical results can be obtained within minutes. For the first time, MALDI-TOF MS has been used to detect resistance promoted by enzymatic modification of antibiotics aside from β-lactamases, expanding the capacity of analysis into new families of antibiotics., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI12/00552 and PI15/00860 to G. B. and PI11-00934 to J. M. R.-M.) integrated in the Plan Nacional de I + D and funded by the Instituto de Salud Carlos III (ISCIII). We also thank the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014 to G. B.), Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad and co-financed by European Development Regional Fund ‘A Way to Achieve Europe’ ERDF. M. O. is financially supported by the Río Hortega Programme of the ISCIII (CM15/00155).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Rapid direct detection of carbapenemase-producing Enterobacteriaceae in clinical urine samples by MALDI-TOF MS analysis

  • Oviaño, Marina
  • de la Luna Ramírez, Cecilia
  • Barbeyto, Luis Pedro
  • Bou, Germán
[Abstract] Objectives: Development of an automated MALDI-TOF MS-based method for the rapid, direct detection of carbapenemase-producing Enterobacteriaceae in clinical urine samples within 90 min of sample reception. Methods: A total of 3041 urine samples were processed by flow cytometry, and a cut-off value of ≥1.5 × 10 5 bacteria/mL was used to select samples for the study. Following these criteria, 608 samples were selected for direct bacterial identification. Detection of carbapenemase activity by MALDI-TOF MS analysis was only performed after reliable direct identification of Gram-negative bacilli. A novel protocol was developed for extracting bacteria from urine samples by using the Sepsityper Kit (Bruker Daltonik, Germany). Carbapenem resistance was detected with imipenem as an antibiotic marker and the results were automatically interpreted using the STAR-BL module of MALDI-TOF Biotyper Compass software (Bruker Daltonik, Germany). Results: The MALDI-TOF MS-based assay yielded direct reliable identification of 91% (503/553) of the samples. The assay showed 100% sensitivity (30/30) and specificity (454/454) for detecting carbapenemase activity within 90 min of sample reception. Isolates included in the study were further characterized by PCR and sequencing, and bla OXA-48 was detected from all isolates that tested positive in the MALDI-TOF MS-based resistance assay. Conclusions: The proposed protocol for the direct analysis of urine samples by MALDI-TOF MS is suitable for use in clinical laboratories to identify bacteria and detect carbapenemase activity, thus saving at least 24-48 h relative to current routine methods., This study was supported by a grant from the Fondo de Investigación Sanitaria (grant number PI12/00552 to G. B. and PI15/00860 to G. B.); Plan Nacional de I + D and Instituto de Salud Carlos III (ISCIII), Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014) co-financed by European Development Regional Fund ‘A Way to achieve Europe’ ERDF. M. O. is financially supported by the Río Hortega Programme of the ISCIII (CM15/00155).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Marine Organisms from the Yucatan Peninsula (Mexico) as a Potential Natural Source of Antibacterial Compounds

  • Pech-Puch, Dawrin
  • Pérez Povedano, Mar Anabel
  • Gómez, Patricia
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Vázquez-Ucha, Juan Carlos
  • Novoa Olmedo, María Lourdes
  • Guillén-Hernández, Sergio
  • Villegas-Hernández, Harold
  • Bou, Germán
  • Rodríguez, Jaime
  • Beceiro Casas, Alejandro
  • Jiménez, Carlos
[Abstract] A total of 51 sponges (Porifera) and 13 ascidians (Chordata) were collected on the coast of the Yucatan Peninsula (Mexico) and extracted with organic solvents. The resulting extracts were screened for antibacterial activity against four multidrug-resistant (MDR) bacterial pathogens: the Gram-negative Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa and the Gram-positive Staphylococcus aureus. The minimum inhibitory concentrations (MICs) of the organic extracts of each marine organism were determined using a broth microdilution assay. Extracts of eight of the species, in particular the Agelas citrina and Haliclona (Rhizoniera) curacaoensis, displayed activity against some of the pathogens tested. Some of the extracts showed similar MIC values to known antibiotics such as penicillins and aminoglycosides. This study is the first to carry out antimicrobial screening of extracts of marine sponges and ascidians collected from the Yucatan Peninsula. Bioassay-guided fractionation of the active extracts from the sponges Amphimedon compressa and A. citrina displayed, as a preliminary result, that an inseparable mixture of halitoxins and amphitoxins and (-)-agelasine B, respectively, are the major compounds responsible for their corresponding antibacterial activities. This is the first report of the antimicrobial activity of halitoxins and amphitoxins against major multidrug-resistant human pathogens. The promising antibacterial activities detected in this study indicate the coast of Yucatan Peninsula as a potential source of a great variety of marine organisms worthy of further research., This work was supported by Grants RTI2018-093634-B-C22 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, co-funded by the FEDER Programme from the European Union, by projects PI15/00860 and PI18/00501 to GB and PI14/00059 and PI17/01482 to AB (Instituto de Salud Carlos III) and BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme INTERREG V A of Spain-Portugal (POCTEP). The study was also funded by projects IN607A 2016/22 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) and GRC2018/039 and Agrupación Estratégica CICA-INIBIC ED431E 2018/03 (Consellería de Educación, Universidades e Formación Profesional) from the Xunta de Galicia (autonomous government of the region). Support was also provided by Planes Nacionales de I+D+i 2013-2016 and ISCIII, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund "A way to achieve Europe" and the operative program Intelligent Growth 2014-2020. J.C.V.U. was financially supported by the pFIS Programme (FI18/00315), M.M.G. was financially supported by a Clara Roy grant (SEIMC) and C.L.M. by IN606A-2019/029. D.P.P. received a fellowship from the program National Council of Science and Technology (CONACYT) of Mexico and the Secretariat of Research, Innovation and Higher Education (SIIES) of Yucatan (Mexico), Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; GRC2018/039, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606A-2019/029
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Pneumonia infection in mice reveals the involvement of the feoA gene in the pathogenesis of Acinetobacter baumannii

  • Poza, Margarita
  • Álvarez-Fraga, Laura
  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Vallejo, J. A.
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Acinetobacter baumannii has emerged in the last decade as an important nosocomial pathogen. To identify genes involved in the course of a pneumonia infection, gene expression profiles were obtained from A. baumannii ATCC 17978 grown in mouse infected lungs and in culture medium. Gene expression analysis allowed us to determine a gene, the A1S_0242 gene (feoA), over-expressed during the pneumonia infection. In the present work, we evaluate the role of this gene, involved in iron uptake. The inactivation of the A1S_0242 gene resulted in an increase susceptibility to oxidative stress and a decrease in biofilm formation, in adherence to A549 cells and in fitness. In addition, infection of G. mellonella and pneumonia in mice showed that the virulence of the Δ0242 mutant was significantly attenuated. Data presented in this work indicated that the A1S_0242 gene from A. baumannii ATCC 17978 strain plays a role in fitness, adhesion, biofilm formation, growth, and, definitively, in virulence. Taken together, these observations show the implication of the feoA gene plays in the pathogenesis of A. baumannii and highlight its value as a potential therapeutic target., This work has been funded by Projects PI15/00860 to GB, CP13/00226 to AB, PI11/01034 to MP and P14/00059 and PI17/01482 to MP and AB, all integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII – General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe”. The study was also funded by the project IN607A 2016/22 (Consellería de Cultura, Educación e Ordenación Universitaria) to G.B. Also supported by Planes Nacionales de I+D+i 2008–2011 / 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014 and REIPI RD16/0016/006) co-financed by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. J. A. Vallejo was financially supported by the Sara Borrell Programme (ISCIII, Spain CD13/00373), J.C. Vázquez-Ucha was financially supported by the Miguel Servet Programme (ISCIII, Spain CP13/00226) and M. Martínez-Guitián was financially supported by the grant Clara Roy (Spanish Society of Clinical Microbiology and Infectious Diseases). We thank M. I. Voskuil (Dept. of Immunology and Microbiology, University of Colorado Medical School, CO, USA) for providing pMo130., Xunta de Galicia. Consellería de Cultura, Educación e Ordenación Universitaria; IN607A 2016/22
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased Antimicrobial Resistance in a Novel CMY-54 AmpC-Type Enzyme with a GluLeu217-218 Insertion in the Ω-Loop

  • Pérez-Llarena, Francisco José
  • Vázquez-Ucha, Juan Carlos
  • Kerff, Frédéric
  • Zamorano, Laura
  • Miró, Elisenda|||0000-0003-2781-6926
  • Cabral, María Póvoa
  • Fleites, Ana
  • Lantero, Marta
  • Martínez-Martínez, Luis
  • Oliver, Antonio|||0000-0001-9327-1894
  • Galleni, Moreno
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Beceiro, Alejandro
  • Bou, German|||0000-0001-8837-0062
During a Spanish surveillance study, a natural variant of a CMY-type β-lactamase related to CMY-2 with a GluLeu217-218 insertion in the Ω-loop (designated CMY-54) was found to increase the minimum inhibitory concentractions to β-lactams in a clinical strain of Escherichia coli. The aim of this study was to characterize CMY-54 by genetic, microbiological, and biochemical analysis. The blaCMY-54 gene is encoded by a plasmid of around 100 kb that hybridizes with K and FIB probes. The genetic context of blaCMY-54 and blaCMY-2 genes was found to be very similar. E. coli expressing CMY-54 under isogenic conditions showed a clear fourfold to eightfold increase in MICs to penicillins, cefotaxime, ceftazidime, and aztreonam compared with CMY-2. The catalytic efficiencies of pure CMY-2 and CMY-54 proteins correlated with their microbiological parameters. CMY-2 protein was more resistant to thermal denaturation than CMY-54, indicating that the Ω-loop of CMY-54 may be wider and more relaxed and probably enables better accommodation of these antimicrobials. Otherwise, the higher stabilization of CMY-2 may induce a slight reduction of the dynamics of this enzyme and primarily affect the hydrolysis of some of the bulkiest antibiotics. In summary, the GluLeu217-218 insertion observed in CMY-54 compared to CMY-2 produces a β-lactamase with a distinctive catalytic efficacy for β-lactam antimicrobials likely caused by an increased flexibility slightly affecting the active site shape, highlighting the relevance of single mutations on the hydrolytic spectrum in class C β-lactamases.